November 18, 2025
Read the full article
11.13.2025
We are pleased to share that Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.
Read more
1.10.2023
Oxford Cancer Analytics is pioneering a new generation of blood based liquid biopsy tests for early cancer detection, and has announced the completion of an additional seed financing round, led by Eka Ventures, with participation from LifeArc, MegaRobo Technologies, Oxford Technology Management, and value-add individual investors.
Read more
12.16.2022
The team from Oxford University Hospitals (OUH) NHS Foundation Trust, the Oxford Radcliffe Biobank and the local spin-out company Oxford Cancer Analytics (OXcan) will recruit 200 participants to identify cancer biomarkers - molecules such as proteins found in blood that are a sign of lung cancer.
Read more
10.20.2021
Ahead of the OXFO annual Demo Day in November, they look at some of the success stories of our past-cohort ventures and how the Elevate accelerator has played a pivotal role in their growth. This snippet focuses on Oxford Cancer Analytics (OXcan), which was one of their portfolio ventures in cohort 3 in 2020.
Read more
For press enquiries, interviews and requests to re-use content, please contact us
.jpg)
%20(1).svg)
